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Abstract
Background: The uptake and adherence of daily oral PrEP has been poor in high-risk populations in South Africa
including young people. We used qualitative research methods to explore user preferences for daily and on-
demand oral PrEP use among young South Africans, and to inform the identification of critical attributes and
attribute-levels for quantitative analysis of user preferences, i.e. a discrete choice experiment (DCE).
Methods: Data were collected between September and November 2018 from eight group discussions and 20 in-
depth interviews with young people 13 to 24 years in Cape Town and Johannesburg. Using a convenience
sampling strategy, participants were stratified by sex and age. Interviewers used a semi-structured interview guide
to discuss several attributes (dosing regimen, location, costs, side effects, and protection period) for PrEP access and
use. Group discussions and in-depth interviews were audio-recorded, transcribed verbatim and translated to
English. We used framework analysis to explore context-specific attributes and attribute-levels for delivering oral
PrEP in South Africa. The adolescent community advisory board, expert and study team opinions were consulted
for the final DCE attributes and levels.
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Results: We enrolled 74 participants who were 51% (n = 38/74) male, had a median age of 18.5 [Interquartile
range = 16–21.25] years, 91% (n = 67/74) identified as heterosexual and 49% (n = 36/74) had not completed 12th
grade education. Using the qualitative data, we identified five candidate attributes including (1) dosing regimen, (2)
location to get PrEP, (3) cost, (4) route of administration and (5) frequency. After discussions with experts and the
study team, we revised the DCE to include the following five attributes and levels: dosing regime: daily, and on-
demand PrEP; location: private pharmacy, public clinic, mobile clinic, ATM); cost: free-of-charge, R50 (~2GBP), R265
(~12GBP); side effects: nausea, headache, rash; and duration of protection: fulltime protection versus when PrEP is
used).
Conclusions: There is limited literature on qualitative research methods describing the step-by-step process of
developing a DCE for PrEP in adolescents, especially in resource-constrained countries. We provide the process
followed for the DCE technique to understand user preferences for daily and on-demand oral PrEP among young
people in South Africa.
Keywords: Discrete choice experiment (DCE), Conjoint analysis, HIV, Oral pre-exposure prophylaxis (PrEP),
Preferences, Adolescents, Young people, South Africa
Background
The prevention of Human Immunodeficiency Virus
(HIV) in young people in South Africa remains a prior-
ity, firstly because it is a preventable chronic condition
which would in turn negate the risk of associated phys-
ical and psychological co-morbidities, and secondly be-
cause of sustained high HIV prevalence and incidence
among adolescents in both South Africa and sub-
Saharan Africa (SSA). Moreover, interventions for HIV
prevention within SSA have had limited effect, despite
high levels of HIV awareness. The limited effect of HIV
prevention interventions is largely attributable to poor
adherence observed in major clinical trials [1–7].
Globally, pre-exposure prophylaxis (PrEP) shows effi-
cacy in preventing HIV amongst males and females [8–
10], with a daily PrEP regimen shown to be effective and
associated with decreasing HIV incidence in heterosex-
ual males and females, males who have sex with males
(MSM), transgender females, and people who inject
drugs (PWID) [2, 9, 11–13]. This regimen has subse-
quently been recommended by the World Health
Organization (WHO) for individuals at high risk for in-
fection [2]. On-demand PrEP, which consists of four
pericoital doses, represents a potentially more cost-
effective approach [14]. However, the on-demand regi-
men is not yet recommended for populations other than
MSM due to the lack of studies and the complexity of
the regimen [15].
Despite availability of PrEP in the public sector to fe-
males 15–24 years in South Africa [16] there is still a
lack of awareness and uptake of PrEP among young
South Africans [17]. The expansion of PrEP is urgently
required across SSA, but can only be optimised by un-
derstanding barriers to PrEP uptake in young people.
Currently, there is no model of PrEP provision for
adolescent males who have been over-looked in HIV
prevention research [15] but contribute to HIV incident
infections [18].
Discrete choice experiments (DCEs), also known as
conjoint analysis, can direct researchers to user needs,
and inform how to best formulate or implement a health
intervention, as DCE allows researchers both to identify
attributes [19] of an intervention that make it attractive
and also to rank the importance of that attribute [20].
The results from DCEs are critical in predicting the suc-
cess of different approaches to implementing particular
healthcare interventions in relevant communities or
populations [21, 22].
DCE-based studies on PrEP preferences in specific co-
horts are lacking, including young people in Africa. Re-
cently, Dubov et al. (2019) performed a DCE to inform
efforts to improve PrEP access and uptake among MSM
in the United States [23]. As for DCE-based studies on
PrEP in the African context, Kuteesa et al. (2019) con-
ducted a DCE-based study investigating fishing commu-
nities in Uganda [24], while Lancaster et al. (2019)
examined preferences among female sex workers (FSWs)
in Malawi [25]. There has also been an increased interest
in using DCEs to explore stakeholder preferences for
healthcare interventions and changes in policy, as well as
using them to support the prioritization, design and im-
plementation of healthcare interventions [20].
The Combined HIV Adolescent Prevention Study
(CHAPS) aims to investigate the acceptability and feasi-
bility of implementing daily and on-demand PrEP
among adolescents in South Africa, Uganda and
Zimbabwe and to determine an on-demand PrEP dosing
schedule for insertive sex in young males [26]. As part of
the social science component, we used qualitative re-
search to develop DCE choice sets to identify attributes
and attribute levels for PrEP delivery among young
people in South Africa.
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The DCE technique can be simplified into four com-
ponents: survey design, piloting and administration to
participants, data analysis, and implement interventions
for the relevant populations, or design further experi-
ments [20, 27]. In this paper we focus on the preliminary
qualitative research conducted to design the DCE for
survey admistration.
Therefore, the aim of this paper is to describe qualita-
tive research methods used to identify and develop the
DCE choice sets and the salient attributes and prefer-
ences for PrEP delivery in young people aged 13–24
years in two South African cities.
Methods
Study design
A qualitative research approach was selected to form
part of a broader rigorous DCE approach, wherein the
qualitative research is good practice in the formative
stage to develop and design the DCE [22]. Data collec-
tion from in-depth interviews (IDIs) allowed for individ-
ual perspectives while group discussions (GDs) provided
data collection within the context of a larger group [28].
Study setting
Data were collected from September to November 2018
at the Perinatal HIV Research Unit (PHRU) in Johannes-
burg and the Desmond Tutu HIV Centre (DTHC) in
Cape Town. Participants were recruited in informal
peri-urban communities established as residential areas
for black South Africans during apartheid, characterized
by overcrowding, unemployment, with limited resources
and service delivery [29].
The PHRU is situated at the Chris Hani Baragwanath
Academic Hospital in Soweto, has conducted research in
HIV prevention, care and treatment for more than 20
years as well as providing healthcare services for the
population of Soweto. Soweto is southwest of Johannes-
burg city in the province of Gauteng, and is estimated to
have a population of ~ 2.5–3 million in an area of 63
km2 [30]. The prevalence of HIV in the Gauteng prov-
ince is 15.2% among 15–49 year olds [31]. The second
site, the DTHC is located in the Klipfontein/Mitchells
Plain sub-district, in the Southern part of the Cape
Town Metro. Compared to other district municipalities
within the Western Cape, the Cape Town Metro bares
the highest population size and prevalence of HIV [31].
Both PHRU and DTHC have a well established Adoles-
cent Community Advisory Boards (ACAB), who are
deeply rooted in their respective communities.
Initial literature review
A literature search was conducted to start the attribute
development process using the terms in Discrete choice
experiment (DCE), Sub-saharan Africa (SSA), South
Africa (SA), pre-exposure prophylaxis (PrEP), young
people. The terms were used in a variety of combina-
tions. While there has been a DCE-based study that in-
cluded preferences concerning PrEP in South Africa
[21], this study conducted in Johannesburg examined a
variety of other HIV and pregnancy prevention methods
along with PrEP, and focused only on female South Afri-
cans in diverse settings. For our study, based on litera-
ture, important attributes for delivering PrEP to young
people included the cost of PrEP, the location of PrEP
dispensaries, and dosage frequency.
Procedures of the qualitative study for developing the
DCE
As part of the larger CHAPS study, qualitative data were
collected between September to November 2018
through eight group discussions (GDs) and 20 in-depth
interviews (IDIs) with young people aged 13 to 24 years;
four GDs and 10 IDIs in Cape Town and Johannesburg,
respectively. In total, 54 participants took part in GDs;
28 in Johannesburg and 26 in Cape Town and a total of
20 participated in IDIs.
Study population, sampling and recruitment process
Fieldworkers used a convenience sampling strategy to
recruit eligible males and females 13–24 years, who were
HIV negative on a rapid HIV test (Soweto used the
ABON HIV 1/2/O Tri-Line Human Immunodeficiency
Virus Rapid Test Device and Cape Town used the Alere
Determine test) and reported sexual activity in the past
3 months. Most participants in our study had moderate
to no prior knowledge about PrEP. In Soweto, partici-
pants for IDIs and GDs were actively recruited through
community organisations, taxi ranks and outside prem-
ises of public meeting places such as shopping malls and
community parks. In Cape Town, participants were re-
cruited through local schools, shopping malls, the li-
brary, word of mouth referrals and walk in at the
research clinic.
Data collection procedures
IDIs and GDs were stratified by age (13–17 years and
18–24 years) and sex (males and females) for Soweto but
not for Cape Town. GDs included mixed sex and age
groups in Cape Town. Prior to the interviews, partici-
pants completed a short five-minute socio-demographic
questionnaire [Additional File 1]. GDs and IDIs were fa-
cilitated by experienced and trained researchers fluent in
English and local languages used (e.g. IsiZulu, IsiSesotho
and IsiXhosa). They were conducted in secure and
private locations at both sites. During the GDs, two re-
searchers were present, one served as the main facilitator
and the other as a note taker and co-facilitator. A semi-
structured guide including open ended questions and
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relevant probes was used to facilitate and guide the dis-
cussions during the IDIs and GDs [Additional File 2].
Participants were allocated a participant identification
number, which was used while completing the demo-
graphic questionnaire and during the GDs and IDIs.
Participants used pseudonyms during all discussions to
maintain anonymity. The IDIs and GDs lasted 36min on
and 100 min on average, respectively. All IDIs and GDs
were audio-recorded, transcribed verbatim, and later
translated to English.
Measures
The brief socio-demographic questionnaire included
questions on sex, age, race, primary home language, sex-
ual orientation, and education level.
Trained qualitative researchers used a semi-structured
interview guide to conduct the GDs and IDIs. The guide
covered topics to identify several attributes for PrEP ac-
cess and use, including: choice of dosing regimen (i.e.
daily versus on-demand PrEP), alternative routes of PrEP
administration (i.e. implant and injection), dispensing lo-
cation (pharmacy, clinic, adolescent/youth centre, doc-
tors office), and time to be spent in obtaining PrEP.
Ethical approval
This study was approved by the Human Research Ethics
Committees of the University of the Witwatersrand and
University of Cape Town. Written study informed con-
sent or assent was obtained from all participants. In So-
weto, parents/ legal guardians provided written informed
consent for participants younger than 18 years. Partici-
pants and parent/legal guardian signed separate forms
for audio-recording. Cape Town had a parental waiver
and did not require parental consent for participants
under 13–17 years. Therefore, for Cape Town, partici-
pants provided written consent regardless of age. Partici-
pants were reimbursed R100 (~ 5GBP) in Johannesburg




Framework analysis, a data analysis approach relevant
for applied research, was used to analyse the data [32].
Framework analysis provides a highly systematic method
of categorizing and organizing data according to key
themes, concepts and emergent categories in grids or
matrices. Transcripts were coded to identify context-
specific attributes and attribute-levels for delivering oral
PrEP in South Africa. Initial coding was conducted by
two trained qualitative research team members at each
site. Initially, the researchers read through four tran-
scripts (two GDs and two IDIs) to gain an understanding
of the data to develop an Excel spreadsheet codebook.
Each transcript was then individually coded using a line
by line technique to assign codes to text. A second ana-
lyst also coded the same transcripts using the line by line
technique to identify codes. Both analysts then met to
discuss codes identified and differences were discussed.
If there was a disagreement among codes, this was dis-
cussed until a common agreement was reached Codes
were then categorized into themes and sub-themes by
both researchers. Themes identified were captured on an
Excel spreadsheet and a comprehensive codebook was
developed. The codebook was shared with the rest of the
team from both sites for final review and input. In order
to ensure data trustworthiness, analysis was conducted
in a consistent manner: we used the same codebook
across all sites, and conducted frequent comparison on
code use through discussion across sites. The main ana-
lyst for this paper reviewed transcripts and coding for all
sites to ensure that the coding was indeed aligned with
transcripts.
Quantitative data analysis
Descriptive statistics and frequencies were used to ana-
lyse socio-demographic characteristics using Statistical
Package for Social Sciences (SPSS) Version 25.0 [33].
Results
Participant characteristics.
The median age of participants was 18.5 years (inter-
quartile range [IQR = 16–21.25]), 51% (n = 38/74) were
male, 91% (n = 67/74) of participants identified as het-
erosexual, all were Black Africans (n = 74/74, 100%), and
49% (n = 36/74) had not completed 12th grade
education.
Qualitative results to identify and develop attributes and
attribute-levels
Table 1 illustrates the full list of all attributes and
attribute-levels, which were identified in consensus
among the two qualitative research analysts. Initially,
eight candidate attributes with respective attribute levels
were identified including (1) Frequency of administra-
tion, (2) side effects, (3) cost, (4) location of PrEP dis-
semination, (5) person responsible for dispensing, (6)
duration of PrEP use, (7) pill intake, and (8) alternative
routes of administration. Attributes and attribute-levels
were identified from the transcripts and prominent par-
ticipants’ quotes were directly extracted to illustrate each
attribute and attribute-level (Table 1).
Frequency of administration
The majority preferred a daily PrEP dosing regimen over
an on-demand PrEP dosing regimen, citing unplanned
sexual intercourse as one of the main reasons. Substance
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Table 1 List of DCE Attributes
Attribute label Lay
terminology









“I prefer taking it [PrEP] daily because as I have said we do not plan to
have sex so if I take it daily even if there is a certain day which chooses
to come up for me to have sex I would know that I have taken the PrEP
medication and I would know that I have protected myself even more
now because I will not take an advantage of it”(IDI, Male,18–24 years,
Soweto)
Daily 20 YES
“I: And then you were saying that you would like to take PrEP when you
are going to have sex? R: Yes. I: But then for how long now? R: For how
long? I may maybe say I would take it [PrEP] 5 days before. If I know that








“Sometimes you know when we vomit you get confused, you don’t know
whether are you sick or you nauseous.” (IDI, Female,18–24 years, Soweto)
Nausea 7 YES
“I occasionally had headaches” (IDI, Female, 18–24 years, Cape Town) Headache 5
“I think that if there is a problem, it will help to show that there is a
problem somewhere, you might get a rash and you might think that you
have an allergy” (GD, Females,18–24 years, Soweto)
Rash 3
Cost How much to
pay for PrEP
“I agree with those who said we get it [PrEP] for free, some families are
struggling financially and I live with my grandmother which means that
from my granny’s money I have to get money for PrEP?” (GD, Females,
18–24 years, Soweto)
Free 6 YES
“R: R50. I: Okay you would buy it [PrEP] for R50 [confirms]. I: And then


















“It will be easy for me to get it [PrEP] from the clinic because I don’t have
money, I don’t have money to buy it, so that’s why I am saying the clinic.
It will be easy for me to get it [PrEP] from the clinic.” (GD, Males,13–17
years, Soweto)
Clinic 25 YES
“I would like to have it [PrEP] if available at the pharmacy and be sold
there, like Shoprite [local low-cost store]. At Shoprite pharmacy no one
will see you when you go there and no one knows you so you will just







“Doctors who are treating HIV because they won’t just give you the pills,
they will even explain why you must use something like that and how
you must use it [PrEP]. (IDI, Male,13–17 years, Soweto)
Doctor 15 NO
“A nurse, a female, but like around our age even if it’s 30, you see but
someone who understands. (GD, Males and Females, 17–22 years, Cape
Town)
Nurse 8
“I would prefer them [HIV counselors] because they are educated to
counsel you first and make sure you are okay before you take something
you don’t know. Nurses can explain but they don’t explain as well as a
counsellor. A counsellor listens to you and you both listen to each other
whereas a nurse just tells you what to do and they don’t even want to








“So knowing that you taking PrEP for the rest of your life you’re safe you
don’t have to worry about anything.” (IDI, Female, 18–24 years, Soweto)
Lifetime 11 NO
“I would take it [PrEP] 5 days before … If I know that on that weekend I




“It should be ten years just like the loop so that we can see how well
people take to it [PrEP]. Like this thing that they put in your arm [refers to
implant]” (GD, Females,18–24 years, Soweto)
Ten years 2
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use was also identified as a factor that leads to un-
planned sex.
“The reason is because you don’t choose when you
will have sex just like Esihle [pseudonym] mentioned
that things such as Nandos, drugs and alcohol and
the next thing you are kissing leading to sex.” (GD,
Females, 18–24 years, Soweto)
“Because I don’t know when I’m going to have sex. I
don’t plan to have sex it just happens.” (IDI, Female,
13–17 years, Cape Town)
There were however some participants who preferred
to take PrEP on demand stating that they might not re-
member to take a pill daily and and that it would be eas-
ier to take PrEP only when they know that they were
going to engage in sexual intercourse.
“I don’t see the reason why I should take it [PrEP]
when I know I am not going to have sex, I am not
going to be at risk.” (IDI, Male, 13–17 years, Cape
Town)
“How am I going to remember to take the pill so I
would rather take it [PrEP] as an on demand.” (GD,
Females, 18–24 years, Soweto)
Side effects
Some participants spoke of side effects from personal
experience and some from information shared by
people using PrEP. Participants stated multiple side
effects, including, headaches, fatigue and “sleepiness”,
that could be experienced when taking PrEP. They
expressed that some side effects might only be experi-
enced for a short period, such as nausea, vomiting,
stomach aches and diarrhea, especially when the body
is not used to the drug.
“When you have just started maybe when you are
not used to it [PrEP], maybe it can make you vomit
but as you keep getting used to it, your body will get
used to the idea that you are always taking tablets.”
(GD, Females, 13–17 years, Soweto)
“For me, I heard that when you start something it
has side effects, right? Other people said that this
PrEP thing that you’re eating causes diarrhea, you
see? Others become thin, others grow spots [a rash].”
(GD, Males and Females, 13–20 years, Cape Town)
Other potential side effects that participants felt could
result from taking PrEP included changes of the skin,
body weight, or developing a rash.
“Side effects like if you take PrEP maybe you can
gain weight. Or maybe you lose weight, do you see?
Or maybe [change] complexion maybe it causes pim-
ples.” (IDI, Male, 13–17 years, Cape Town)
“You might get a rash and you might think that you
have an allergy.” (GD, Females, 18–24 years,
Soweto)
Cost of PrEP
The pricing of PrEP was based on GD and IDI partici-
pants’ suggestions. The actual cost of a months supply
of daily generic Truvada (tenofovir-disoproxil and emtri-
citabine) as PrEP, as approximately R200 (~ 9GBP), was
also taken into consideration when contextualizing the
attribute-levels for the cost of PrEP. Some participants
preferred PrEP to be free, while others expressed they
would willing to pay. A few participants reported that
they would not be able to access PrEP if there was a
price attached to it due to a low socio-economic status.
To buy PrEP would mean choosing between buying
basic essential goods versus PrEP.
Table 1 List of DCE Attributes (Continued)
Attribute label Lay
terminology





Pill intake Number of
desired pills to
take
“I: So how many pills a day do you think a person should take? R: One a
day. I: Ok one right why do you think so? R: No people will get bored in
taking two or three pills. (IDI, Female, 13–17 years, Cape Town)
One pill 13 NO








“P: Implant. I: Why? P: you do not have to go to the clinic if it is free. You
don’t have to go to the clinic every time to get it” (IDI, Female, 18–24
years, Soweto)
Implant 6 NO
“Since I am a forgetful person, I wish PrEP can be injectable just like
contraception” (GD, Males and Females, 15–23 years, Cape Town)
Injection 20
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“I agree with those who said we get it [PrEP] for free,
some families are struggling financially and I live
with my grandmother which means that from my
granny’s money I have to get money for PrEP?” (GD,
Females, 18–24 years, Soweto)
“I would prefer to get it [PrEP] for free.” (IDI, Male,
13–17 years, Cape Town)
Participants suggested various prices of PrEP, ranging
from R10 (50 cents) to a maximum of R300 (14GBP).
The varying prices were also justified with the number
of tablets that one person could afford and were also
based on a monthly supply. Overall, participants stated
it would be beneficial for them to be able to access PrEP
to protect themselves against HIV, even when there is a
cost attached to accessing PrEP.
“P: I would be willing to even if okay for us especially
in the hood [neighbourhood] there it could cost
maybe R20 each I would meet means and hustle
hard for them so that I know I am on a safe side. I:
So R20 for a bottle? P: Each pill I: R20 for one pill.”
(IDI, Male, 18–24 years, Soweto)
“R: R50. I: Okay you would buy it [PrEP] for R50
[confirms]. R: Uhm. I: And then how long would it
[PrEP] last you? R: A month.” (IDI, Female, 18–24
years, Cape Town)
Location of PrEP dissemination
It was important to get an understanding on where par-
ticipants would like to access PrEP. Since services are
free at the local clinics this is where some participants
opted to access PrEP.
“It will be easy for me to get it [PrEP] from the clinic
because I don’t have money…, I don’t have money to
buy it [PrEP], so that’s why I am saying the clinic. It
will be easy for me to get it [PrEP] from the clinic.”
(GD, Males, 13–17 years, Soweto)
“I would wish to get it [PrEP] from the clinic. Yes, a
public clinic because at the clinic you are given pills,
it is not known what these are for. They are handed
out…when you go looking for a PrEP pill, you should
receive it in a place for pills [pharmacy].” (IDI, Fe-
male, 18–24 years, Cape Town)
Other participants opted for pharmacies, as they stated
it was more private and confidential compared with a
local clinic. Participants also stated that accessing PrEP
through a pharmacy would be faster without long
queues.
“I would like to have it [PrEP] available at the phar-
macy and be sold there. No one will see you when
you go there {pharmacy] and no one knows you so
you will just buy it [PrEP].” (GD, Males and Fe-
males, 15–23 years, Cape Town)
Person responsible for dispensing PrEP
Participants stated that doctors, nurses and HIV
counsellors would be best suited to dispense PrEP,
because they were regarded as experienced and
trained in testing and treating HIV, as well as being
knowledgeable about prescribing and explaining PrEP
to young people. However, some participants pre-
ferred a younger over an older health care provider
to dispense PrEP.
“I would prefer them [HIV counselors] because they
are educated to counsel you first and make sure you
are okay before you take something you don’t know.
Nurses can explain but they don’t explain as well as
a counsellor. A counsellor listens to you and you
both listen to each other whereas a nurse just tells
you what to do and they don’t even want to know
about your concerns.” (GD, Females, 18–24 years,
Soweto)
“A person for young people who is able to reach
out to young people, someone friendly. So it may
happen that she handles such department. She
has to be young person so that we girls are able
to talk to her and boys can have a male to talk
to.” (GD, Males and Females, 15–23 years, Cape
Town)
PrEP dosing
Participants discussed different dosing periods for tak-
ing PrEP. These differed from the timeframe to take
PrEP to be protected for the next sexual intercourse,
to the time period PrEP should be taken once started
on it.
“I would prefer if they take it [PrEP] once a day but
for a lifetime.” (IDI, Male, 18–24 years, Soweto)
“I may maybe say I would take it [PrEP] five days
before [sex]. If I know that on that weekend I am go-
ing to be seen by my partner, something like tha-
t.”(IDI, Male, 13–17 years, Cape Town)
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“It [PrEP] should be ten years just like the loop so
that we can see how well people take to it. Like this
thing that they put in your arm.” (GD, Females, 18–
24 years, Soweto)
Pill intake
Overall, participants stated that they would be willing to
take one pill or two pills per dose. However, the majority
preferred to only take one pill, especially when taking it
over a longer period of time. If taking two pills, partici-
pants would prefer to take one in the morning and the
other in the evening.
“One a day…people will get bored in taking two or
three pills.” (IDI, Female, 13–17 years, Cape Town)
“It is easy to take one pill because if you take more
than 1 pill the more you get discouraged to take it
because you will be like so many pills why? Why do
I have to take pills 3 times a day.” (IDI, Female, 18–
24 years, Soweto)
Alternative route of administration
During the GDs and IDIs, alternative routes of adminis-
tration were discussed. Participants reported they would
chose an implant or injectable as it would only need to
be administered once and would not require returning
to the clinic as frequently compared to using oral PrEP.
“Since I am a forgetful person, I wish PrEP can be in-
jectable just like contraception.” (GD, Males and Fe-
males, 15–23 years, Cape Town)
“Implant because injection people are scared of pain
whenever we talking about injection comes pain in
our heads but implant it is something which you do
once off maybe then it last for a certain period which
is intended for it to last.” (IDI, Male, 18–24 years,
Soweto)
Expert opinion
The study team consulted two experts experienced in
designing and implementing DCEs in South Africa.
Through an iterative process of discussions with these
experts four of the initial eight candidate attributes were
retained with three attribute-levels, each, except for the
dosing regimen attribute, which consisted of two
attribute-levels, daily and on-demand PrEP. Table 1 indi-
cates whether the attribute identified during the qualita-
tive analysis process was retained after the discussion
phase with the experts (last column). The discussion was
aimed at selecting the most relevant attributes with a
maximum of three attribute-levels each. This was also
important to ensure the DCE incorporates a manageable
number of attributes and level options to ensure that
participants were not overwhelmed with the number of
choice sets within the DCE. Consultation with other
local team members ensured the language used for the
attributes and attribute-levels was understandable and
relevant within the South African context. For the loca-
tion of PrEP dissemination it was deemed relevant to in-
clude a third attribute level, mobile clinic, as this has
been a feasible approach to provide integrated health
care, counselling services and dispensing of medication
in underserved communities in Cape Town [34]. The
final attributes and attribute-levels for the DCE included:
dosing (daily and on-demand PrEP), location (private
pharmacy, public clinic, mobile clinic), cost (free-of-
charge, ZAR50 (~2GBP), ZAR200 (~ 9GBP)), and (4)
side effects (nausea, headache, rash). After the iterative
revision process, SAS was used to develop a statistically
efficient and balances fractional factorial design of the
DCE. Using SAS Enterprise Guide 7.15 (SAS Institute
Inc., Cary, NC, USA) and the attributes identified in the
qualitative study, the maximum possible number of attri-
bute combinations was 23 × 31 [35]. A smaller factorial
design was further developed using the D-Efficiency cri-
teria reducing the choice sets to a feasible number of 6.
The final DCE was constructed with a total of six binary
choice sets with two scenario descriptions and graphics
of the attribute-levels and participants can chose be-
tween Choice A and Choice B (Fig. 1).
Permission was granted from the iPrevent study team
to utilize illustrations for public community health clinic
and private pharmacy as part of our DCE choice sets
[36]. For the other illustrations the following sources are
acknowledged: Daily PreP [37]; on-demand PrEP [38];
cost illustrations [39, 40]; nausea [39]; headache [41];
rash [42].
Pilot testing of the DCE with community advisory board
members
To ensure a community engaged approach to the DCE
development, the ACAB of the PHRU ratified the DCE
choice sets as developmentally and contextually appro-
priate [20]. ACAB members regarded the number of
choice sets as manageable, easy to understand, user-
friendly and easy to follow. In addition, ACAB members
agreed the illustrating graphics included in the DCE
choice sets were complementary, relevant and context-
specific for the attributes and related levels.
Discussion
We explored PrEP delivery preferences among young
people from a peri-urban setting in a multisite context
in South Africa to develop a DCE. There are few
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methodological literature that describes the process to
systematically infer attributes and its levels for a DCE,
which is considered an important technique to better
understand and provide guidance on user preferences
for interventions and products [20, 22]. Previous re-
search in South Africa and SSA that used a DCE focused
on hypothetical HIV prevention methods [43], HIV test-
ing, HIV and family planning services [21]. One multi-
national study conducted in seven countries among key
user groups aged 16 - ≥41 years to elicited acceptability
of PrEP and factors to determine uptake [44].
Even though DCEs are increasingly used in the field of
sexual and reproductive health, there is limited research
on young people’s PrEP preferences in developing coun-
tries. Young people are considered a high risk group of
acquiring HIV infection and important beneficiaries in
accessing PrEP, yet oral PrEP uptake is low amongst
South African youth [17]. Amongst a sample of 772
young people aged 16–24 years in the Eastern Cape,
South Africa, only 1.7% had used PrEP [17]. Once young
people initiate on PrEP, a substantial proportion do not
persist with it [45]. Our documentation of the DCE
methodology provided a unique opportunity for targeted
investigation on how to best implement PrEP amongst
this population to support uptake in resource-limited
settings.
During the qualitative interviews, young people
expressed an initial preference for daily over on-demand
PrEP. Participants stated that the use of daily PrEP
would ensure protection for spontaneous or unantici-
pated sexual activities. Previous research shows that
young people are often less likely to anticipate sex,
which also includes communication and control within
relationships [25]. This may be particularly true for
young females, as they often have less decision making
power and be less likely able to negotiate when sex oc-
curs [46]. This might impact on chosing daily versus on-
demand PrEP. In addition, young people are at high risk
of non-adherence to medications, including contracep-
tion, ART or other chronic medications [47]. While it
may be more difficult for young people adhering to a
strict fixed pre-intercourse and/or post-intercourse PrEP
dosing regimen, it may also impact on optimal adher-
ence to a daily PrEP regimen.
Participants in our study discussed the tradeoffs be-
tween locations to access PrEP with costs and confiden-
tiality. Participants opted for accessing PrEP at their
local clinics, mainly because services would be free.
Others preferred to access PrEP at a pharmacy, for ease
of access, privacy and confidentiality. Stigma and dis-
crimination are commonly known barriers to accessing
public health care facilities and lead for young people to
Fig. 1 Example of a DCE choice set. Permission was granted from the iPrevent study team to utilize illustrations for public community health
clinic and private pharmacy as part of our DCE choice sets [34]. For the other illustrations the following sources are acknowledged: Daily PreP
[35]; on-demand PrEP [36]; cost illustrations [37, 38]; nausea [37]; headache [39]; rash [40]
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less likely engage in sexual and reproductive health care,
including HIV services [48, 49]. Therefore, alternative lo-
cations for accessing PrEP might promote PrEP uptake
among young people and support privacy and confiden-
tiality, which was an important aspect for young people
in our sample when getting PrEP. During a South Afri-
can based demonstration project amongst females, PrEP
initiation was high in youth-orientated, family planning
and mobile outreach clinics [45]. Offering PrEP at differ-
ent types of locations could be a suitable delivery model
for young people. This may mitiage additional barriers,
such as transportation, long distance to dispensing sites,
and healthcare provider attitutes [50, 51]. In the South
African setting, an integrated reproductive health care
delivery model to access PrEP is feasible amongst fe-
males [45].
Participants in our study discussed their willingness to
use alternative modalities for PrEP administration in-
cluding injectables and implants. Current research is
underway that tests the effectivenss of long-acting inject-
able formulations and intra-vaginal rings and potential
alternatives to oral PrEP [52]. Further evaluations are re-
quired that focus on the willingness and perceptions of
alternative application methods of PrEP amongst young
people and not just for adults [53].
To better ensure that the final DCE was reflective of
youth preferences we were able to incorporate a com-
munity engaged approach. The ACABs were actively in-
volved in reviewing the choice sets for content,
language, graphics and layout. This phase afforded the
research team the opportunity to test the DCE choice
sets supported response efficiency and content validity
within the DCE [54, 55]. A youth engaged approach has
been shown to work well in other settings, such as inter-
ventions for mental health, substance use and HIV pre-
vention interventions [56, 57].
Next steps are to deliver the final DCE in a larger
CHAPS survey and then to assess the preferences of
young people for PrEP delivery in two South African cit-
ies, Soweto and Cape Town. It is anticipated that the re-
sults will provide important insights on how to align the
implementation of PrEP to be most accessible and bene-
ficial for young people, who present a key population in
the HIV prevention response.
Limitations
A few participants had prior PrEP experience, but the
larger sample had limited to no prior exposure to PrEP.
To avoid a potential bias based on those with PrEP ex-
perience, we included recruitment to locations outside
of the clinic setting. Many participants that discussed
topics related to PrEP access and use, drew from experi-
ence with other medication or from reports of others
who took PrEP or where exposed to PrEP before. This
was particularly true when they discussed the location to
access PrEP and possible side effects. Limited prior
knowledge on PrEP might have influenced participant’s
responses. However, this was largely mitigated by the
fact that discussions during the phase with experts con-
firmed the relevancy of the attributes and attribute-level
identified during the qualitative interview phase.
At present, there is more biological evidence to sup-
port on-demand PrEP in males who have sex with males
and less evidence to support such dosing options in fe-
males [58]. This qualitative research was conducted to
explore participant preferences when provided with the
choice for on-demand versus daily PrEP without expli-
citly stating that there was insufficient evidence for on-
demand dosing in females. Previous research in adoles-
cents showed a preference for using PrEP at periods of
higher risk [59] – providing the impetus to better under-
stand what it is that young people want. Therefore, our
approach was to explore what ideal youth preferences
were despite the biological evidence. Future research
could explore how responses among young people
would differ based on this biological limitation.
Conclusions
There are few qualitative research methods studies de-
scribing the step-by-step process of developing a DCE
for PrEP in adolescents, especially in resource-
constrained countries. Using a systematic and robust ap-
proach, we use a developed and designed a DCE with at-
tributes and levels for PrEP uptake that can be tested in
young people in SA. We provide the process followed
for the DCE technique to understand user preferences
for daily and on-demand oral PrEP among young people
in South Africa.
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